{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:21:26Z","timestamp":1789744886054,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:00:00Z","timestamp":1487289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:00:00Z","timestamp":1487289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Whether bisphosphonates could enhance the effect of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) patients with EGFR mutation and bone metastases (BM) remains unknown. EGFR mutation status were collected from 1560 patients with NSCLC and BM. 356 NSCLC patients with EGFR mutation and BM were identified. Among them, 91 patients received EGFR-TKIs alone and 105 patients received EGFR-TKIs plus bisphosphonates as first-line therapy. Comparing to TKIs alone, EGFR-TKIs plus bisphosphonates had a statistically significant longer progression-free survival (PFS: 11.6 vs. 9.3 months; HR\u2009=\u20090.68, P\u2009=\u20090.009), while a similar overall survival (OS: 20.5 vs. 19.5 months; HR\u2009=\u20090.95, P\u2009=\u20090.743) in patients with EGFR-mutant NSCLC and BM. The incidence of skeletal-related events in combined group was numerically lower than that in EGFR-TKIs alone group (29.7% vs. 39.4%, P\u2009=\u20090.147). In multivariate analysis, EGFR mutation was found to be a significant independent prognostic factor for OS in NSCLC patients with BM (HR\u2009=\u20090.710, P\u2009=\u20090.021). In conclusion, EGFR mutation was the significant independent prognostic factor for OS and the addition of bisphosphonates to EGFR-TKIs could enhance the antitumor effect of EGFR-TKIs in patients with EGFR-mutant NSCLC and BM.<\/jats:p>","DOI":"10.1038\/srep42979","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T10:36:36Z","timestamp":1487327796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases"],"prefix":"10.1038","volume":"7","author":[{"given":"Guowei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruirui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,17]]},"reference":[{"key":"BFsrep42979_CR1","doi-asserted-by":"publisher","first-page":"13200","DOI":"10.1038\/ncomms13200","volume":"7","author":"Y Liu","year":"2016","unstructured":"Liu, Y. et al. Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun. 7, 13200 (2016).","journal-title":"Nat Commun"},{"key":"BFsrep42979_CR2","doi-asserted-by":"crossref","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. (2016).","DOI":"10.3322\/caac.21349"},{"key":"BFsrep42979_CR3","unstructured":"SEER Stat Fact Sheets: Lung and Bronchus Cancer. In. National Cancer Institute 2015."},{"key":"BFsrep42979_CR4","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s11999-007-0051-0","volume":"466","author":"H Sugiura","year":"2008","unstructured":"Sugiura, H., Yamada, K., Sugiura, T., Hida, T. & Mitsudomi, T. Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res. 466, 729\u2013736 (2008).","journal-title":"Clin Orthop Relat Res"},{"key":"BFsrep42979_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1164\/rccm.201503-0440SO","volume":"192","author":"S Vicent","year":"2015","unstructured":"Vicent, S., Perurena, N., Govindan, R. & Lecanda, F. Bone metastases in lung cancer. Potential novel approaches to therapy. Am J Respir Crit Care Med. 192, 799\u2013809 (2015).","journal-title":"Am J Respir Crit Care Med"},{"key":"BFsrep42979_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2016.03.014","volume":"96","author":"MB Oliveira","year":"2016","unstructured":"Oliveira, M. B., Mello, F. C. & Paschoal, M. E. The relationship between lung cancer histology and the clinicopathological characteristics of bone metastases. Lung Cancer. 96, 19\u201324 (2016).","journal-title":"Lung Cancer"},{"key":"BFsrep42979_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jtho.2015.10.001","volume":"11","author":"LE Hendriks","year":"2016","unstructured":"Hendriks, L. E., Hermans, B. C., van den Beuken-van Everdingen, M. H., Hochstenbag, M. M. & Dingemans, A. M. Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review. J Thorac Oncol. 11, 155\u2013173 (2016).","journal-title":"J Thorac Oncol"},{"key":"BFsrep42979_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.5306\/wjco.v5.i2.149","volume":"5","author":"I Roato","year":"2014","unstructured":"Roato, I. Bone metastases: When and how lung cancer interacts with bone. World J Clin Oncol. 5, 149\u2013155 (2014).","journal-title":"World J Clin Oncol"},{"key":"BFsrep42979_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.lungcan.2015.04.007","volume":"89","author":"M Kuchuk","year":"2015","unstructured":"Kuchuk, M. et al. The incidence and clinical impact of bone metastases in non-small cell lung cancer. Lung Cancer. 89, 197\u2013202 (2015).","journal-title":"Lung Cancer"},{"key":"BFsrep42979_CR10","doi-asserted-by":"publisher","first-page":"18670","DOI":"10.1038\/srep18670","volume":"5","author":"S Daniele","year":"2015","unstructured":"Daniele, S. et al. Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Sci Rep. 5, 18670 (2015).","journal-title":"Sci Rep"},{"key":"BFsrep42979_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.lungcan.2007.03.013","volume":"57","author":"A Tsuya","year":"2007","unstructured":"Tsuya, A., Kurata, T., Tamura, K. & Fukuoka, M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer. 57, 229\u2013232 (2007).","journal-title":"Lung Cancer"},{"key":"BFsrep42979_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry, D. H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 29, 1125\u20131132 (2011).","journal-title":"J Clin Oncol"},{"key":"BFsrep42979_CR13","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","volume":"7","author":"GV Scagliotti","year":"2012","unstructured":"Scagliotti, G. V. et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 7, 1823\u20131829 (2012).","journal-title":"J Thorac Oncol"},{"key":"BFsrep42979_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.lungcan.2007.08.026","volume":"59","author":"YY Li","year":"2008","unstructured":"Li, Y. Y. et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer. 59, 180\u2013191 (2008).","journal-title":"Lung Cancer"},{"key":"BFsrep42979_CR15","first-page":"581","volume":"20","author":"S Lu","year":"2008","unstructured":"Lu, S. et al. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Oncol Rep. 20, 581\u2013587 (2008).","journal-title":"Oncol Rep"},{"key":"BFsrep42979_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/CAD.0b013e3283400a05","volume":"22","author":"YY Li","year":"2011","unstructured":"Li, Y. Y. et al. Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression. Anticancer Drugs. 22, 89\u201398 (2011).","journal-title":"Anticancer Drugs"},{"key":"BFsrep42979_CR17","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1002\/cncr.21530","volume":"104","author":"B Ory","year":"2005","unstructured":"Ory, B. et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer. 104, 2522\u20132529 (2005).","journal-title":"Cancer"},{"key":"BFsrep42979_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2008.12.019","volume":"278","author":"JW Chang","year":"2009","unstructured":"Chang, J. W. et al. Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells. Cancer Lett. 278, 17\u201326 (2009).","journal-title":"Cancer Lett"},{"key":"BFsrep42979_CR19","doi-asserted-by":"crossref","unstructured":"Huang, C. Y. et al. Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study. Oncotarget. (2015).","DOI":"10.18632\/oncotarget.5515"},{"key":"BFsrep42979_CR20","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1677\/erc.1.01061","volume":"12","author":"D Melisi","year":"2005","unstructured":"Melisi, D. et al. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer. 12, 1051\u20131058 (2005).","journal-title":"Endocr Relat Cancer"},{"key":"BFsrep42979_CR21","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1002\/ijc.24470","volume":"125","author":"K Zarogoulidis","year":"2009","unstructured":"Zarogoulidis, K. et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer. 125, 1705\u20131709 (2009).","journal-title":"Int J Cancer"},{"key":"BFsrep42979_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","volume":"3","author":"V Hirsh","year":"2008","unstructured":"Hirsh, V. et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 3, 228\u2013236 (2008).","journal-title":"J Thorac Oncol"},{"key":"BFsrep42979_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.lungcan.2009.04.020","volume":"67","author":"KJ Pandya","year":"2010","unstructured":"Pandya, K. J. et al. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer. 67, 330\u2013338 (2010).","journal-title":"Lung Cancer"},{"key":"BFsrep42979_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/cas.12448","volume":"105","author":"H Murakami","year":"2014","unstructured":"Murakami, H. et al. Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group. Cancer Sci. 105, 989\u2013995 (2014).","journal-title":"Cancer Sci"},{"key":"BFsrep42979_CR25","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.ctrv.2013.10.001","volume":"40","author":"SL Wood","year":"2014","unstructured":"Wood, S. L., Pernemalm, M., Crosbie, P. A. & Whetton, A. D. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 40, 558\u2013566 (2014).","journal-title":"Cancer Treat Rev"},{"key":"BFsrep42979_CR26","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman, G. D. Mechanisms of bone metastasis. N Engl J Med. 350, 1655\u20131664 (2004).","journal-title":"N Engl J Med"},{"key":"BFsrep42979_CR27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nature04524","volume":"440","author":"DH Jones","year":"2006","unstructured":"Jones, D. H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 440, 692\u2013696 (2006).","journal-title":"Nature"},{"key":"BFsrep42979_CR28","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/CCO.0b013e32835d720b","volume":"25","author":"S Peters","year":"2013","unstructured":"Peters, S. & Meylan, E. Targeting receptor activator of nuclear factor-kappa B as a new therapy for bone metastasis in non-small cell lung cancer. Curr Opin Oncol. 25, 137\u2013144 (2013).","journal-title":"Curr Opin Oncol"},{"key":"BFsrep42979_CR29","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1158\/0008-5472.CAN-13-0305","volume":"73","author":"A Sawant","year":"2013","unstructured":"Sawant, A. & Ponnazhagan, S. Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. Cancer Res. 73, 4606\u20134610 (2013).","journal-title":"Cancer Res"},{"key":"BFsrep42979_CR30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","volume":"6","author":"WD Travis","year":"2011","unstructured":"Travis, W. D. et al. International association for the study of lung cancer\/american thoracic society\/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 6, 244\u2013285 (2011).","journal-title":"J Thorac Oncol"},{"key":"BFsrep42979_CR31","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1002\/cncr.28725","volume":"120","author":"M Zhao","year":"2014","unstructured":"Zhao, M. et al. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. Cancer. 120, 2299\u20132307 (2014).","journal-title":"Cancer"},{"key":"BFsrep42979_CR32","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/JTO.0000000000000487","volume":"10","author":"C Wu","year":"2015","unstructured":"Wu, C. et al. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules. J Thorac Oncol. 10, 778\u2013783 (2015).","journal-title":"J Thorac Oncol"},{"key":"BFsrep42979_CR33","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.lungcan.2014.03.011","volume":"84","author":"W Li","year":"2014","unstructured":"Li, W. et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer. 84, 295\u2013300 (2014).","journal-title":"Lung Cancer"},{"key":"BFsrep42979_CR34","doi-asserted-by":"crossref","first-page":"7902","DOI":"10.18632\/oncotarget.2302","volume":"5","author":"J Li","year":"2014","unstructured":"Li, J. et al. miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. Oncotarget. 5, 7902\u20137916 (2014).","journal-title":"Oncotarget"},{"key":"BFsrep42979_CR35","doi-asserted-by":"crossref","unstructured":"Jiang, T. et al. EGFR TKIs plus WBRT demonstrated no survival benefit than TKIs alone in NSCLC patients with EGFR mutation and brain metastases. J Thorac Oncol. (2016).","DOI":"10.1016\/j.jtho.2016.05.013"},{"key":"BFsrep42979_CR36","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1097\/JTO.0b013e3181b68e5a","volume":"4","author":"F De Marinis","year":"2009","unstructured":"De Marinis, F. et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol. 4, 1280\u20131288 (2009).","journal-title":"J Thorac Oncol"},{"key":"BFsrep42979_CR37","first-page":"57","volume":"17","author":"Y Sun","year":"2014","unstructured":"Sun, Y. et al. [Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)]. Zhongguo Fei Ai Za Zhi. 17, 57\u201372 (2014).","journal-title":"Zhongguo Fei Ai Za Zhi."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep42979.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42979","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep42979.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T01:37:00Z","timestamp":1671845820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep42979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,17]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,3,24]]}},"alternative-id":["BFsrep42979"],"URL":"https:\/\/doi.org\/10.1038\/srep42979","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,17]]},"assertion":[{"value":"2 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42979"}}